Breast cancer is the one of the most common cancers and causes a significant disease burden. Currently, postmastectomy radiotherapy (PMRT) is indicated for breast cancer patients with higher risk of recurrence, such as those with positive surgical margins or high-risk breast cancer (T3 with positive lymph nodes, ≥4 positive lymph nodes or T4 disease). Whether PMRT should be used in intermediate-risk breast cancer (T3 with no positive lymph nodes or T1-2 with 1-3 positive lymph nodes) is contentious. Rates of breast reconstruction postmastectomy are increasing in countries like Australia, and PMRT usage in such settings is another area of active research. Ongoing trials are also assessing the safety and efficacy of hypofractionated PMRT, a clinical scenario now widely accepted for early-stage breast cancer. This brief review is unique in that it aims to examine three current and controversial aspects of the PMRT field (PMRT in intermediate-risk breast cancer, PMRT in conjunction with breast reconstruction and its hypofractionation). To achieve this aim, we discuss available and emerging literature and guidelines to offer insights important to the PMRT field. Current literature suggests that PMRT could play a role in improving the overall survival rate and in reducing locoregional recurrence in intermediate-risk breast cancer. In terms of recommending a timing or type of breast reconstruction best suited to the setting of PMRT, we found that individual patient preferences and circumstances need to be considered alongside a multidisciplinary approach. Research into PMRT hypofractionation safety and efficacy is ongoing and its place remains to be elucidated.